Adial Pharmaceuticals Secures Expanded Patent for Genotype-Based Treatment of Alcohol Use Disorder
Adial Pharmaceuticals receives a patent for expanded genotype coverage in treating alcohol use disorder with its drug AD04.Quiver AI SummaryAdial Pharmaceuticals, a clinical-stage biopharmaceutical company...
Adial Pharmaceuticals Announces Topline Results For Onwardâ„¢ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an...
Adial Pharmaceuticals to Announce Topline Results of ONWARDâ„¢ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET...